The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index; 49 of the 109 sources its claims cite were checked for support.
Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through
Open accessAbstract
Lentiviral vectors (LVs) play an important role in gene therapy and have proven successful in clinical trials. LVs are capable of integrating specific genetic materials into the target cells and allow for long-term expression of the cDNA of interest. The use of non-integrating LVs (NILVs) reduces insertional mutagenesis and the risk of malignant cell transformation over integrating lentiviral vectors. NILVs enable transient expression or sustained episomal expression, especially in non-dividing cells. Important modifications have been made to the basic human immunodeficiency virus (HIV) structures to improve the safety and efficacy of LVs. NILV-aided transient expression has led to more pre-clinical studies on primary immunodeficiencies, cytotoxic cancer therapies, and hemoglobinopathies. Recently, the third generation of self-inactivating LVs was applied in clinical trials for recombinant protein production, vaccines, gene therapy, cell imaging, and induced pluripotent stem cell (iPSC) generation. This review discusses the basic lentiviral biology and the four systems used for generating NILV designs. Mutations or modifications in LVs and their safety are addressed with reference to pre-clinical studies. The detailed application of NILVs in promising pre-clinical studies is also discussed.
Overview
CoChat Summary
TL;DR
This review argues that non-integrating lentiviral vectors (NILVs) are a safer alternative to integrating lentiviral vectors because they reduce insertional mutagenesis and malignant transformation risk while still supporting transient or episomal expression. It surveys NILV design and applications in vaccination, cell-type differentiation, site-directed integration, and gene therapy, emphasizing that NILVs are especially useful in non-dividing or slowly dividing cells.
Key findings
- NILVs are designed to avoid genomic integration by mutating integrase or LTR attachment sequences; the paper says this reduces insertional mutagenesis and lets vector DNA persist as non-replicating episomes, especially in non-dividing cells.
- Compared with other non-integrating methods, the paper states episomal plasmids and Sendai viral (SeV) vectors have the highest efficiency and only occasional integration, while NILVs still have the advantage of broad cell/tissue transduction and higher transfer efficiency in dividing and non-dividing cells.
- In vaccination, the review reports that a single NILV immunisation encoding West Nile virus envelope induced a strong B-cell response and early, long-lasting protective immunity; another NILV approach against OVA in mice showed complete protection against thymoma.
- In cell-type differentiation, the paper notes that APOA-II-GFP-positive human embryonic stem cells produced hepatic progenitors with 99% expressing hepatoblast markers, and it highlights iPSC production as a promising but still underused NILV application.
Methods
- Narrative review of lentiviral biology, NILV design, limitations, and clinical/pre-clinical applications.
- The paper synthesizes prior studies across pre-clinical and clinical contexts, including vaccination, iPSC generation, site-directed integration, and gene therapy.
- Main analysis is comparative and descriptive, drawing contrasts among NILVs, integrating lentiviral vectors, and other non-integrating systems such as SeV, episomal plasmids, AAV, and EBV-based approaches.
Limitations
- The paper states NILVs lose episomes during rapid cell division and therefore have reduced long-term expression in highly proliferative cells.
- It also states NILVs can show reduced transgene expression compared with integrating vectors, and that residual integration is still not acceptable for some clinical applications.
- Evident from the text: this is a review, so it does not present a new primary dataset or new experimental results of its own.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
36 Valid · 12 Not valid · 45 Not checked · 47 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Vaccinia virus [81], Zika virus [82], and human cytomegalovirus [83] have also been investigated in pre-clinical studies to test their immune responses.”
§ Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through > 4. Clinical Application of NILVs > 4.1. Vaccination
What the sources say
- Could not verifycites [81] Odegard, 2015, Virological and Preclinical Characterization of a Dendritic Cell Targeting, Integration-deficient Lentiviral Vector for Cancer Immunotherapy, J. Immunother. sourceExperimental — accuracy not yet measured
Citation [83] is attached to the human cytomegalovirus part of the sentence. The Results section, “Memory CD8 T Cells Induced by ID-VP02 Expand and Exhibit Antiviral Function” (page unavailable), describes preclinical immune-response testing with vaccinia virus, not human cytomegalovirus. Searches for human cytomegalovirus, HCMV, and CMV found no passage addressing that part of the claim. (LLM, conf=0.76)
- Supportedcites [82] Ku, 2020, A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus, Mol. Ther. source
The Results section reports pre-clinical testing of a Zika vaccine in mice, including measurements of IgG and neutralizing antibody responses (page not provided). This confirms the Zika-virus portion attributed to citation [82]; vaccinia virus and human cytomegalovirus are assigned to other citations. (LLM, conf=0.94)
- Misattributedcites [83] Deng, Y., Guan, J., Wen, B., Zhu, N., Chen, H., Song, J., Yang, Y., Wang, Y., and Tan, W. (2013). Induction of Broadly Neutralising HCV Antibodies in Mice by Integration-Deficient Lentiviral Vector-Based Pseudotyped Particles. PLoS ONE, 8. sourceExperimental — accuracy not yet measured
For the vaccinia-virus portion of the sentence, the cited paper reports a preclinical mouse study of an HCV lentiviral-vector vaccine, not a vaccinia-virus study (Discussion; Immunisation of Mice, page unavailable). Vaccinia appears only in a References entry naming Deng et al. (2009) as the study of a vaccinia-virus prime-boost regimen in mice. The Zika and human-cytomegalovirus portions have separate citations and are not judged here. (LLM, conf=0.84) It matches “A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice” (2009) instead.
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“It is also possible for insertional mutagenesis to occur due to gene dysregulation at the LV integration site within or near a coding region of the host genome [6].”
§ Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through > 1. Introduction
What the sources say
- Supportedcites [6] Schlimgen, 2016, Risks Associated with Lentiviral Vector Exposures and Prevention Strategies, J. Occup. Environ. Med. source
The paper’s Abstract states that insertional mutagenesis results from gene dysregulation where an LVV integrates within or near a coding region of the host genome. This directly supports the citing sentence. (LLM, conf=0.95)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Alternatively, non-integrating LV (NILVs) can be designed by introducing mutations in the LV integrase or Δatt (LTR integrase attachment) site [8,9].”
§ Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [8] Engelman, 1995, Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication, J. Virol. source
- Supportedcites [9] Shaw, 2014, Design and potential of non-integrating lentiviral vectors, Biomedicines source
Section 2.1 describes integrase mutations and mutations in the LTR integrase attachment sites as alternative ways to develop NILVs. Table 1’s caption explicitly identifies Δatt as an LTR integrase attachment-site mutation. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the SeV vector is known as being “ex-gene-free”, several researchers are still unsure of its safety in producing clinical-grade iPSC lines, as the avoidance of transgene integration passively depends on the cell passage [64].”
§ Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through > 3. Non-Integrating Lentiviral Vector (NILV) Design > 3.1. Comparisons of NILVs with Other Non-Integrating Methods
What the sources say
- Partly supportedcites [64] Nakanishi, 2012, Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine, Curr. Gene Ther. sourceExperimental — accuracy not yet measured
The Future Perspectives section cautions that ex-gene-free status may not suffice for clinical-grade iPSC lines. The Nuclear Reprogramming with SeV Vectors section says cell passage passively eliminates the wild-type vector genome, but SeV avoids chromosomal integration independently of cell passage. The claim conflates vector elimination with avoidance of integration; no page numbers are available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is also well-known for its high transduction efficiency compared to other methods [63].”
§ Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through > 3. Non-Integrating Lentiviral Vector (NILV) Design > 3.1. Comparisons of NILVs with Other Non-Integrating Methods
What the sources say
- Partly supportedcites [63] Fusaki, 2009, Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome, Proc. Jpn. Acad. Ser. B sourceExperimental — accuracy not yet measured
The Introduction describes SeV vectors as very efficient at introducing foreign genes, and the Results (Expression of exogenous genes in human fibroblasts) report GFP expression in almost all infected cells at a low viral dose. The Discussion says iPSC-generation efficiency was higher than with other methods, but the paper does not make that comparison for transduction efficiency itself. (LLM, conf=0.84)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
59 more claims · 14 with their cited sources checked
Create a free account to see all 140 claims and to verify the 19 references still open.
- It may state two separate claims as one. 57
- Probably not a substantial claim. 27
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 1×
“This reduces the possibility of creating RCL events compared to the third-generation system, and in fact this generation is considered the safest to date [15].”
BackgroundHuman induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815 · cited 1×
“Self-inactivating (SIN) plasmids in the third-generation system harbour a large deletion of TATA box, Sp1, and NF-kB transcription factor binding sites that further reduce viral replication [13].”
BackgroundGeneration of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814
Chemically defined conditions for human iPSC derivation and culture
Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1593 · Cited by 1,447
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Cited by
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges
Mengstie, M. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.895713 · Cited by 168
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 163
“Non-integrating lentiviruses have been developed to avoid viral integration into random sites in the host genome which carries the risk of disrupting the function of normal genes or causing cancer (Gurumoorthy et al., 2022).”
BackgroundAmanat, M., Nemeth, C. L., Fine, A. S., Leung, D. G., & Fatemi, A. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112389 · Cited by 79
A CRISPR-Cas Cure for HIV/AIDS
Hussein, M., Molina, M. A., Berkhout, B., & Herrera-Carrillo, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021563 · Cited by 75
Metadata
- Authors
- Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H.
- Affiliations
- University Kebangsaan Malaysia Medical Centre (MY)
- Universiti Sains Malaysia (MY)
- Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, 50603 Kuala Lumpur, Malaysia
- Corresponding author
- Nordin, Fazlina
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2022-01-05
- Volume
- 10
- Issue
- 1
- Pages
- 107
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC8773317
- OpenAlex
- W4206000278
- Semantic Scholar
- 89ed1ab6f173298a897c0276807aa5f0789d0b09
- Cited by
- 69
- References
- 143
- Citations by year
- 2026: 7 · 2025: 27 · 2024: 19 · 2023: 10 · 2022: 5
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Higher Education (FRGS/1/2020/SKK06/UKM/03/4)
- National University of Malaysia (FF-2020-327)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- lentiviral vectors, gene therapy, transient expression, insertional mutagenesis, HIV-based vectors, self-inactivating lentiviral vectors, primary immunodeficiency, hemoglobinopathies, recombinant protein expression, vaccines, induced pluripotent stem cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. https://app.cochat.ai/papers/10.3390/biomedicines10010107
- The paper
- Gurumoorthy, N., Nordin, F., Tye, G. J., Wan Kamarul Zaman, W. S., & Ng, M. H. (2022). Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. Biomedicines. https://doi.org/10.3390/biomedicines10010107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.